EnGeneIC Ltd. to Present at BIO CEO & Investor Conference 2016

Feb 03, 2016, 08:00 ET from EnGeneIC Ltd.

NEW YORK and SYDNEY, Feb. 3, 2016 /PRNewswire/ -- EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced today that it will present at the BIO CEO & Investor Conference to be held February 8-9, 2016, in New York City.

Himanshu Brahmbhatt, Ph.D., and Jennifer MacDiarmid, Ph.D., Joint-CEOs and directors of EnGeneIC, will be attending the conference and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Dr. MacDiarmid will provide an overview of the Company's business, groundbreaking EDV™ nanocell technology platform and rapidly advancing development pipeline during her presentation.

Event:


The 18th Annual BIO CEO & Investor Conference

Date: 


Tuesday, February 9, 2016

Presentation Time: 


1:00 pm (Eastern Time) 

Location:


The Waldorf Astoria New York; Park North Room

About EnGeneIC and the EDV™ Nanocell Technology 
EnGeneIC is a clinical stage biopharmaceutical company focused on developing its proprietary bacterially-derived EDV™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only found within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug, siRNA, or miRNA payload at high concentrations, intracellularly. The EDV™ nanocell platform has shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and USA.

For more information, please visit www.engeneic.com

U.S. Investor Contact:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. 
+1-212-375-2664
jdrumm@tiberend.com  

U.S. Media Contact:
Tiberend Strategic Advisors, Inc. 
Amy S. Wheeler 
+1-646-362-5750
awheeler@tiberend.com

Australia Media Contact:
Felicity Moffatt
+61-418-677701
felicity@mdmedia.net.au

 

SOURCE EnGeneIC Ltd.



RELATED LINKS

http://engeneic.com